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Abstract
Background: Endostatin is a potent endogenous anti-angiogenic agent which inhibits tumour
growth. A non-synonymous coding polymorphism in the Endostatin gene is thought to affect
Endostatin activity. We aimed to determine the role of this Endostatin polymorphism in breast
cancer pathogenesis and any influence on serum Endostatin levels in healthy volunteers. Endostatin
protein expression on a breast cancer micro array was also studied to determine any relationship
to genotype and to breast cancer prognosis.
Methods: The 4349G > A (coding non-synonymous) polymorphism in exon 42 of the Endostatin
gene was genotyped in approximately 846 breast cancer cases and 707 appropriate controls. In a
separate healthy cohort of 57 individuals, in addition to genotyping, serum Endostatin levels were
measured using enzyme linked immunosorbant assay (ELISA). A semi-quantitative assessment of
Endostatin protein expression on immunostained tissue micro arrays (TMA) constructed from
breast cancer samples of patients with genotype data was performed.
Results: The rare allele (A) was significantly associated with invasive breast cancers compared to
non-invasive tumours (p = 0.03), but there was no association with tumour grade, nodal status,
vascular invasion or overall survival. There was no association with breast cancer susceptibility.
Serum Endostatin levels and Endostatin protein expression on the tissue micro array were not
associated with genotype.
Conclusion: The Endostatin 4349A allele is associated with invasive breast cancer. The Endostatin
4349G > A polymorphism however does not appear to be associated with breast cancer
susceptibility or severity in invasive disease. By studying circulating levels and tumour Endostatin
protein expression, we have shown that any influence of this polymorphism is unlikely to be
through an effect on the levels of protein produced.
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Background
Endostatin, a fragment of collagen 18-1α, was first identi-
fied in the conditioned medium of a hemangioendotheli-
oma cell line as a potent inhibitor of angiogenesis and
tumour growth [1]. The parent molecule releases Endosta-
tin after proteolytic digestion by elastase and cathepsin L
[2]. Endostatin inhibits endothelial cell proliferation and
migration and induces apoptosis [3-5]. Several mecha-
nisms have been postulated to explain the anti-angiogenic
effects of Endostatin. One such mechanism is the high
affinity of Endostatin for heparin explained by the pres-
ence of an extensive basic patch formed by 11 arginine res-
idues. The interaction with heparin can interfere with the
binding of basic fibroblast growth factor (bFGF) to cell
surface heparan sulphate proteoglycans thereby inhibit-
ing FGF growth signalling [6]. Alternatively, Endostatin
can inhibit VEGF-induced migration of endothelial cells
independent of the heparin binding epitope [7]. VEGF
expression can also be reduced by anti-angiogenic factors
such as Endostatin and Angiostatin resulting in impaired
angiogenesis and reduced tumour growth [8]. In exponen-
tially growing endothelial cells, many genes are down reg-
ulated by Endostatin including early response genes, cell
cycle-related genes, and genes regulating apoptosis inhib-
itors, mitogen-activated protein kinases, focal adhesion
kinase, G-protein-coupled receptors mediating endothe-
lial growth, a mitogenic factor, adhesion molecules, and
cell structure components [9]. The downregulation of pro-
angiogenic genes and the upregulation of anti-angiogenic
genes, together with the regulation of other genes unre-
lated to angiogenesis demonstrates that endostatin is
involved in the complex interplay and extensive network-
ing of the various signalling pathways in the microvascu-
lar endothelium [10].
The anti-tumour effect of Endostatin has been shown in a
number of different solid tumours including melanoma,
fibrosarcoma, renal cell carcinoma, mammary carcinoma
and ovarian carcinoma [3]. In addition, in mice bearing
Lewis lung carcinoma, T241 fibrosarcoma and B16F10
melanoma resistance to Endostatin suppression does not
develop despite tumours being allowed to re-grow in
between repeated treatment cycles [11].
Endostatin is one of the most potent and specific endog-
enous angiogenic inhibitors to enter clinical trials [12].
Several phase I studies have shown that the drug is well
tolerated and without side effects [13-15].
The COL18A1 gene (which includes the Endostatin gene)
was mapped in 1994 to the chromosomal region 21q22.3
by fluorescence in situ hybridization [16], with around 20
gene polymorphic variants identified[17]. One single
nucleotide variant (G to A change) resulting in an aspartic
acid to asparagine change (D104N) in exon 42 is in the
encoding region for Endostatin and is a conserved site in
both humans and mice. It is thought that the mutant mol-
ecule is stable but might impair Endostatin-induced ang-
iogenesis inhibition by mechanisms that are still not clear
[17]. Presence of the mutant allele results in a 2.5 times
increased risk of prostate cancer [17], whereas in multiple
myeloma there is no association with increased risk[18].
The aim of the study was to evaluate the Endostatin poly-
morphism in breast cancer susceptibility, severity, any
association with serum Endostatin levels in healthy peo-
ple and Endostatin protein expression on a breast cancer
tissue micro array. The relationships between Endostatin
protein expression and clinico-pathologic parameters in
breast cancer were also evaluated.
Methods
Case and control selection
The design and methodology of the case control model
has been previously described [19,20]. The cases include
women diagnosed with breast cancer being followed up at
the Royal Hallamshire Hospital in Sheffield and Rother-
ham District General Hospital and controls were recruited
from asymptomatic women attending the Sheffield Breast
Screening Service for regular screening mammograms.
The study was restricted to white Caucasians, as there were
insufficient individuals from other ethnic groups for
meaningful analysis. The South Sheffield Research Ethics
Committee approved the study [Ref. no. SS98/137] and
informed written consent was obtained from all subjects.
Demographic, environmental risk factors and family his-
tory data were recorded for all breast cancer cases and
mammography screening controls, using a standard ques-
tionnaire. Pathological data (including tumour grade,
lymph node status and presence of vascular invasion)
were obtained from medical records and validated by an
experienced histopathologist (SSC). Data on disease
recurrence and overall survival were obtained from the
hospital records and the Trent Cancer Registry. The data
was entered by trained personnel and stored in a Micro-
soft Access database and maintained by a dedicated data-
base administrator. The data was validated for all the
records (by SPB and database manager).
DNA extraction and Genotyping
From all participants, venous blood was collected in
EDTA-vaccutainers and frozen at -20°C and later used for
DNA extraction as described previously [21]. The
sequence containing the polymorphism of interest [G > A
nucleotide change resulting in D > N change in the amino
acid sequence] was downloaded from GenBank (Acces-
sion numbers AL163302 and AF018081). The genomic
sequence and coding sequence were aligned with each
other using BLAST in NCBI website. The boundaries of the
exons were noted and exon 42 together with the polymor-BMC Cancer 2007, 7:107 http://www.biomedcentral.com/1471-2407/7/107
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phic site of interest was identified. An assay was designed
to genotype the Endostatin polymorphism by the 5'nucle-
ase PCR method, using the ABI/PE Biosystems Taqman™
system. Specifically designed primer and probe sequences
included the forward primer (5'-GGCTCTGTTCTCAG-
GCTCTGA-3'), reverse primer (5'-GGCTCTCAGAGCT-
GCTCACA-3'), 6-carboxy-fluorescein (FAM)-labelled
probe (5'-FAM-TCTCCTTTAACGGCAAGGACGTCC-
TAMRA-3') and 6-carboxy-4,7,2',7'-tetrechlorofluorescein
(TET)-labelled probe (5'-TET-CTTCTCCTTTGACG-
GCAAGGACG-TAMRA-3'). PCR amplification was carried
out at a final volume of 25 μl. The final concentrations of
the PCR constituents were 0.8 ng/μl genomic DNA tem-
plate, 50 nM forward primer, 300 nM reverse primer, 50
nM FAM-labelled probe, 50 nM TET-labelled probe and 1
× (12.5 μl) Universal PCR mastermix (PE Biosystems)
containing optimised buffer components and Rox refer-
ence dye. The PCR amplification cycle was 50°C for 2 min
and 95°C for 10 min, followed by 40 cycles of 95°C for
15 seconds and 62°C for 1 min. Levels of FAM and TET
fluorescence were determined and allelic discrimination
was carried out using the ABI 7200 Sequence Detector (PE
Biosystems). Quality control for the genotyping results
was achieved by using only 72 of the 96 wells in each of
the plates for the individual DNA samples subjected to
PCR. Six to eight wells were allocated to 'no sample' con-
trols, 'common homozygous' controls and 'rare
homozygous' controls, in addition to re-evaluation of
samples with indeterminate results. The common and rare
homozygous controls included samples tested previously
and demonstrated to be 'common homozygous' and 'rare
homozygous' respectively. An example of the genotyping
results obtained is shown in Figure 1.
Serum Endostatin protein Estimation
Serum samples (in addition to genotyping data) were col-
lected from a group of non-smoking healthy postmeno-
pausal women (with no history of cancers) attending
breast screening. Serum was collected in a serum separator
tube, allowed to clot for at least 30 minutes and then cen-
trifuged for 10 minutes. Serum samples were aliquoted
into 4–5 eppendorf tubes and frozen at -20°C. Endostatin
protein levels were determined using the Quantikine®
human Endostatin immunoassay kit (R&D Systems,
Europe; catalog number DNST0). This assay employs the
quantitative sandwich enzyme immunoassay technique
using a mouse monoclonal antibody specific for human
Endostatin.
Endostatin Tissue Micro array
A tissue micro array was constructed from archived paraf-
fin embedded tumour samples of patients from the cancer
cohort used in this study. From suitable areas on the
tumour blocks, triplicate tissue cylinders with a diameter
of 0.6 mm were punched using custom made precision
instruments (Beecher Instruments Inc., Sun Prairie, US)
and transferred into recipient paraffin blocks in a specific
orientation. Five μm sections from the array blocks were
dried, deparaffinized and rehydrated before blocking any
endogenous peroxidase with a solution of 3% hydrogen
peroxide in methanol. The sectioned tissue was then sub-
jected to antigen retrieval by microwave treatment in 0.01
M sodium citrate solution.pH 6. This was followed by a
standard immuno-histochemical staining procedure for
Endostatin protein using goat anti-human Endostatin
antibody (R&D systems Inc., UK) at a dilution of 1:4. This
antibody was produced in goats immunized with puri-
fied, E. coli-derived, recombinant human Endostatin.
Human tonsillar tissue was used as a positive control. The
slides containing samples in triplicate were assessed for
Endostatin staining (by an independent observer SSC
who was blinded to the genetic and clinical data) and
scored semi-quantitatively. Each core on the micro array
was given a score from zero (no stain) to three (intense
staining) depending on the intensity of the Endostatin
staining by the tumour cells (Figure 2). The sum of all the
three scores for each specimen was calculated to give a
score on a scale of 0 to 9. For those with only two scores,
the third was taken as the average of the first two and sum
of the three was calculated. Specimens with one or no
assessable cores were excluded.
Data and statistical analyses
All data were entered initially into a Microsoft Access data-
base and exported to SPSS (version 12.0.1 for Windows)
for statistical analyses. Univariate non-parametric meth-
ods were used to test for associations between genotype
and phenotype. Kaplan Meier curves and the log rank test
were used for the survival analyses. Multivariate analyses
and correction for multiple testing were not performed in
view of the exploratory nature of this study. Results were
considered statistically significant at p < 0.05.
Results
Endostatin polymorphism and breast cancer susceptibility 
and severity
The demographic characteristics and comparability of
case and control cohorts have been reported previously
[19,20]. Briefly, the case and control groups were all Cau-
casian and female. Table 1 shows the baseline characteris-
tics of the population. There were no significant
differences in the percentage of postmenopausal women,
age at menarche and age at menopause between the can-
cer and control groups. The women in the control groups
were however younger, were younger when first pregnant,
had more children, were less likely to have a family his-
tory of breast cancer and were more likely to have smoked.
Survival analyses were done in the cohort of women with
invasive breast cancer who received surgery as a first line
treatment and in whom follow up data was available. TheBMC Cancer 2007, 7:107 http://www.biomedcentral.com/1471-2407/7/107
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median (interquartile range) follow up period for this
group (n = 571) was 69 (48 and 102) months.
The observed genotype frequencies of the Endostatin pol-
ymorphism are in Hardy Weinberg equilibrium i.e., simi-
lar to expected genotype frequencies. The Chi-square
goodness of fit statistic (p values at 1 df) was χ2 = 2.71 (p
= 0.10). Rare allele carriage rates (combining GA and AA
genotypes) were used for further analyses as the numbers
with AA genotype were minimal across the different
groups. Table 2 shows that the allele carriage rates for this
polymorphism is not different between the control and
cancer groups and in subgroups classified according to
family history and age at diagnosis. In the breast cancer
cohort, there were 44 patients with preinvasive tumours.
The allele carriage rates is different in the pre-invasive and
the invasive cohorts (p = 0.033) (Figure 3). Patients with
the A allele have a higher risk of developing invasive
breast cancers when compared to the non-invasive group
(Odds Ratio = 4.17; 95% CI = 1–17.5). The rare allele car-
riage rates within subgroups of invasive breast cancer
(defined by tumour size, tumour grade, nodal status, vas-
cular invasion and oestrogen receptor status) demon-
strated no significant association between the Endostatin
polymorphism and breast cancer severity (as measured by
the listed prognostic factors) (Table 3). The Endostatin
polymorphism did not influence overall survival in
patients with invasive breast cancer (N = 568; log rank sta-
tistic = 0.52; df = 1; p = 0.47).
Endostatin polymorphism and serum Endostatin protein 
levels
Of the cohort of non smoking healthy peri or post meno-
pausal women (with no history of cancers) attending
breast screening, serum Endostatin levels by ELISA and
the Endostatin genotype results were available for 57 indi-
viduals. The median (inter-quartile range) serum Endosta-
tin levels was 89.5 (82.5–100.5) ng/ml. The genotype
distributions in this cohort were also in Hardy Weinberg
equilibrium (χ2 = 0.16; p = 0.69). Comparison of the
Endostatin levels between the carriers and non carriers of
the mutant allele showed no significant difference
between groups [MannWhitney U test; z = -0.12; p =
0.90].
Endostatin polymorphism and protein staining on breast 
cancer tissue micro array
Following the Endostatin immunostaining of the micro-
arrays, 255 different tumour samples were available for
analysis. Figure 2 shows the staining patterns of Endosta-
tin in breast cancer. 8.2% of the tumours showed no stain-
ing with Endostatin. The median (inter-quartile range)
score on the entire cohort was 4 (3–6). The Endostatin
immunostaining scores on the breast cancer tissue micro
Endostatin genotyping results obtained from the Taqman Sequence Detection System Figure 1
Endostatin genotyping results obtained from the Taqman Sequence Detection System. Samples are categorised into common 
homozygous or 1:1 (red), rare homozygous or 2:2 (blue) and heterozygous or 1:2 (green) groups.BMC Cancer 2007, 7:107 http://www.biomedcentral.com/1471-2407/7/107
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array showed no association with tumour size (Jonck-
heere Terpstra observed test statistic = 8265.5; p = 0.35),
nodal status (Mann-Whitney U test; z = -0.33; p = 0.74),
tumour grade (Jonckheere Terpstra observed test statistic
= 10557.5; p = 0.23), vascular invasion (Mann-Whitney U
test; z = -0.5; p = 0.62) and oestrogen receptor status
(Mann-Whitney U test; z = -0.43; p = 0.66). To assess the
impact of Endostatin staining on overall survival, the
Endostatin scores were recoded into an ordinal variable
comprising three levels: Minimal staining (scores up to 3),
moderate staining (from 3.01 to 6.99) and intense stain-
ing (from 7 to 9). Survival data and Endostatin scores
were available on 179 patients with invasive breast cancer
(Figure 4). Although there is no significant association
between Endostatin staining and overall survival, the data
suggests that tumours with reduced Endostatin staining
tend to do worse. The average levels of Endostatin staining
were compared between carriers and non carriers of the
rare Endostatin allele and no significant difference was
found (Mann-Whitney U test; z = -0.52; p = 0.60).
Discussion
Endostatin is thought to be important in the preventing
tumour progression mainly by inhibition of angiogenesis
[22]. This has resulted in its evaluation in clinical trials in
advanced cancer [23]. The role of the non-synonymous
coding Endostatin polymorphism (4349G > A) in exon 42
of the Collagen 18A gene in carcinogenesis has been eval-
uated in several cancers including that of the prostate
[17,24,25], large bowel [26], multiple myeloma [18] and
leukaemia [27]. Although the rare allele was initially sug-
gested to be associated with increased prostate cancer risk
[17], a recent large study has negated this association [25].
The frequency of the rare allele in our Caucasian control
cohort (8.2%) is similar to other Caucasian populations,
but much higher than in Black and Chinese populations
[17,18,25,27]. This study has not demonstrated a signifi-
cant association between the polymorphism and breast
cancer susceptibility in the UK population. However,
Table 1: Demographic characteristics of the 'breast cancer' and 'screening control' groups.
CHARACTERISTICS CASES CONTROLS P VALUE
Age N 847 712 P < 0.01#
Median (IQR) 62 (54–70) 57 (53–61)
Ever Smoked N 844 712 P < 0.01~
Yes 295 (35%) 316 (44.4%)
No 549 (65%) 396 (55.6%)
Post Menopausal N 849 712 P = 0.34~
Yes 547 (64.4%) 476 (66.9%)
No 302 (35.6%) 236 (33.1%)
Age at Menarche N 840 709 P = 0.05#
Median (IQR) 13 (12–14) 13 (12–14)
Age at Menopause N 485 420 P = 0.38#
Median (IQR) 50 (46–52) 50 (47–52)
Number of children N 849 712 P < 0.01#
Median (IQR) 2 (1–3) 2 (2–3)
Age at first pregnancy N 705 646 P < 0.01#
Median (IQR) 24 (21–27) 23 (20–26)
Family history of breast cancer N 850 712 P < 0.01~
Yes 234 (27.5%) 153 (21.5%)
No 616 (72.5%) 559 (78.5%)
IQR – Inter quartile range;
# – Mann Whitney U test; ~- Chi square test with continuity correction
Negative (a), weak (b), moderate (c) and strong (d) Endosta- tin staining in invasive breast cancer Figure 2
Negative (a), weak (b), moderate (c) and strong (d) Endosta-
tin staining in invasive breast cancer. Magnification ×200.BMC Cancer 2007, 7:107 http://www.biomedcentral.com/1471-2407/7/107
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within the breast tumour cohort, the rare allele (A)
appears to be associated with invasive breast cancers (p =
0.03). The rare allele carriage rates in the non-invasive
tumour group (4.5%; n = 44) is significantly lower than
the rates in the invasive breast cancer group (16.6%; n =
784) and in the control group (n = 16.3%; n = 707). It is
well recognised that angiogenesis and vascular stroma for-
mation precedes the development of invasive breast dis-
ease [28,29]. Only a proportion of women with DCIS will
however progress to invasive disease [30] and the mecha-
nisms underlying this transformation are still unclear. The
finding therefore of a genetic variant predisposing to inva-
sion needs further consideration as the role of Endostatin
as an inhibitor of tumour angiogenesis and thereby
growth is well recognised. Among those with invasive
breast cancer, there is no association between the poly-
morphism and standard prognostic factors such as
tumour size, tumour grade, axillary lymph nodal status,
vascular invasion and oestrogen receptor status. However,
we also acknowledge that this association would not be
significant if subjected to correction for multiple testing
and needs further investigation in a larger cohort of
patients and in different populations.
A study reported recently [31] on the Brazilian population
has shown that the AA polymorphism may be associated
with increased breast cancer risk, although the risk in het-
erozygotes were lower than the risk in GG homozygotes.
No other association was found between the Endostatin
polymorphism and pathological features including histo-
logical type, grade, ER and PR status and TNM stage. The
study also did not find any relationship between the
Endostatin genotype and serum levels [31]. The limita-
tions of this study however were the inclusion of both
genders and different races, which has the potential for
population stratification.
We have not shown any effect of the Endostatin polymor-
phism on serum levels in healthy older women, which is
in accordance with previous reports and with the hypoth-
esis that the mutant protein has an altered function but a
stable structure [17]. Endostatin protein expression on an
invasive breast cancer tissue micro array has also shown
no association with the Endostatin polymorphism or with
standard prognostic markers in breast cancers (tumour
size, tumour grade, nodal status, vascular invasion and
oestrogen receptor status). We also found no association
Table 2: Rare allele carriage rates in breast cancer and controls
Groups Rare allele (A) carriage rate (%) Odds Ratio (95% CI) Test statistic (p value)#
Cancer Controls
Overall 136/846 (16.1%) 115/707 (16.3%) 0.99 (0.75–1.29) ×2 = 0.001; p = 0.97
Positive family history* 38/231 (16.5%) 22/153 (14.4%) 0.17 (0.66–2.07) ×2 = 0.16; p = 0.69
Negative family history* 98/615 (15.9%) 93/554 (16.8%) 0.94 (0.69–1.28) ×2 = 0.1; p = 0.75
Young patients** vs. controls 20/130 (15.4%) 115/707 (16.3%) 0.94 (0.56–1.57) ×2 = 0.01; p = 0.90
# Pearson's chi-square test (with Yates correction where applicable)
*Family history: either first or second-degree relative with breast cancer
**Young cancer patients: </= 50 years of age
Table 3: Rare allele carriage rates in subgroups of invasive breast cancer
Tumour Severity Rare allele carriage rates (%) Test statistic (p value)#
Tumour size Less than 2 cm 68/414 (16.4%) p = 0.94$
2 to 5 cm 42/270 (15.6%)
More than 5 cm 2/17 (11.8%)
Tumour Grade Grade 1 28/149 (18.8%) ×2 = 1.99; p = 0.37
Grade 2 57/329 (17.3%)
Grade 3 33/239 (13.8%)
Nodal Invasion Absent 82/498 (16.5%) ×2 = 0.23; p = 0.63
Present 40/219 (18.3%)
Vascular invasion Absent 86/515 (16.7%) ×2 = 1.06; p = 0.30
Present 17/135 (12.6%)
Oestrogen Receptor Status Present 48/264 (18.2%) ×2 = 0.91; p = 0.34
Absent 13/98 (13.3%)
# Pearson's chi-square test (with Yates correction where applicable)
$ Fisher's exact test.BMC Cancer 2007, 7:107 http://www.biomedcentral.com/1471-2407/7/107
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with overall survival, but in view of the reduced length of
follow up information and the rarity of the end points
(death), larger numbers of patients are required to dem-
onstrate any significant effect on survival. The fact that the
Endostatin staining did not correlate with other prognos-
tic markers may suggest that Endostatin could have an
independent effect on survival. We acknowledge that esti-
mating 'protein levels' in tumour tissue by Western blot
analyses may have provided information of more value
that that obtained semi-quantitatively by Immunohisto-
chemistry.
Conclusion
This study has shown no significant association between
the 4349G > A coding non-synonymous Endostatin poly-
morphism and breast cancer susceptibility. The polymor-
phism is also not associated with tumour severity in
patients with invasive breast cancer. We have however
shown for the first time that Endostatin genotype may be
associated with progression to invasive breast disease.
Although the polymorphism is not associated with
Endostatin levels in serum and tumour tissue, it may
potentially affect Endostatin function. Further studies
exploring the differences in genotype frequencies among
those with non-invasive and invasive cancer and expres-
sion patterns in DCIS are needed.
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